异动解读 | 歌礼制药-B盘中大跌9.64%,配股折让近10%引发抛售

异动解读
Aug 19

歌礼制药-B(01672.HK)今日盘中大跌9.64%,报16.5港元,成交额达8.68亿港元。该股价暴跌主要源于公司宣布的配股计划。

根据公司公告,歌礼制药于8月19日(交易时段前)与控股股东JJW12 Limited及配售代理签订配售及认购协议。根据协议,控股股东将以每股16.45港元的价格配售5240万股现有股份,并认购2882万股新股。配售价较8月18日收市价18.26港元折让约9.9%,这一显著折让引发了市场的抛售潮。

此次配股募集资金净额约4.68亿港元,公司表示90%将用于皮下注射多肽及口服多肽候选药物相关的肥胖症临床试验研发,剩余10%用作营运资金及其他一般公司用途。值得注意的是,此次配股完成后,控股股东的总持股比例将从约62.21%降至约58.03%。尽管公司强调此举旨在推进研发项目,但投资者对股权稀释表现出担忧,进一步加剧了股价跌势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10